Tools
Stock profile

SI-BONE, Inc. (SIBN)

SIBN · Latest close $23.54 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$23.54
As of Nov 18, 2026
Tracked funds holding
1 of 149
2026 Q2 13F filings
Opened / added
0 / 1
vs previous quarter
Trimmed / exited
0
vs previous quarter

SI-BONE, Inc. (SIBN) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $8.5M sold). Latest close $23.54 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 17, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-8.5M
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

First Eagle Investment Management — 1 tracked fund hold SIBN. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 33 sales ($8.5M). Insider trading

Often held alongside

BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
First Eagle Investment Management0.02%768,941ADDED (+20.3%) Q3 filed Nov 10

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +37.9% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

25.6011.052024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding170 of 8,857 filers
Long-only filers among them168
Change vs 2026 Q1-2 net · 164 entered · 166 exited
Shares reported, all filers47,423,972
Reported value, all filers$772.0M

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustrySurgical & Medical Instruments & Apparatus (SIC 3841)
Revenue · FY2025$200.9M
Net income · FY2025$-18.9M
Total assets · FY2025$238.6M
Shares outstanding44,818,575
Market cap (at latest close)$1.1B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 29, 2026.

Short interest

Shares short · Oct 15, 20264,704,576
Share of shares outstanding10.50%
Days to cover8.67

Shares short at recent settlements — Jul 31, 2026: 5.1M · Aug 14, 2026: 5.3M · Aug 31, 2026: 5.6M · Sep 15, 2026: 5.9M · Sep 30, 2026: 5.1M · Oct 15, 2026: 4.7M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 29, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 29, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 33 sales by 4 insiders ($8.5M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 17, 2026Maheshwari AnshulChief Op & Financial OfficerSell1,715$23.19$39.8KSEC filing
Nov 17, 2026FRANCIS LAURAChief Executive OfficerSell1,901$23.18$44.1KSEC filing
Nov 16, 2026Maheshwari AnshulChief Op & Financial OfficerSell2,476$23.31$57.7KSEC filing
Nov 16, 2026Maheshwari AnshulChief Op & Financial OfficerSell2,189$23.34$51.1KSEC filing
Nov 16, 2026PISETSKY MICHAEL A.Chief Legal OfficerSell1,854$23.32$43.2KSEC filing
Nov 16, 2026PISETSKY MICHAEL A.Chief Legal OfficerSell1,871$23.31$43.6KSEC filing
Nov 16, 2026FRANCIS LAURAChief Executive OfficerSell3,892$23.33$90.8KSEC filing
Nov 16, 2026FRANCIS LAURAChief Executive OfficerSell2,235$23.33$52.1KSEC filing
Nov 16, 2026FRANCIS LAURAChief Executive OfficerSell3,203$23.32$74.7KSEC filing
Nov 16, 2026FRANCIS LAURAChief Executive OfficerSell3,651$23.33$85.2KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Oct 5, 2026ANSHUL MAHESHWARIOfficer1,731$31.3KOct 5, 2026SEC filing
Aug 24, 2026ANSHUL MAHESHWARIOfficer11,636$232.3KAug 24, 2026SEC filing
Aug 24, 2026DAVID & LAURA FRANCIS JOINT REV TRU/A DTD 01/03/2003Director, Officer25,972$518.4KAug 24, 2026SEC filing
Aug 21, 2026DAVID & LAURA FRANCIS JOINT REV TRU/A DTD 01/03/2003Director, Officer3,923$76.4KAug 21, 2026SEC filing
Aug 21, 2026ANSHUL MAHESHWARIOfficer11,228$218.7KAug 21, 2026SEC filing
Aug 20, 2026DAVID & LAURA FRANCIS JOINT REV TRU/A DTD 01/03/2003Director, Officer51,884$1.0MAug 20, 2026SEC filing
Aug 19, 2026ANSHUL MAHESHWARIOfficer5,747$110.0KAug 19, 2026SEC filing
Aug 3, 2026THE JEFFREY W DUNN LIVING TRUST DTD 05/17/2012Director80,000$1.4MAug 3, 2026SEC filing
May 29, 2026TIMOTHY E DAVIS JRDirector3,500$49.5KMay 29, 2026SEC filing
Mar 12, 2026MIKA NISHIMURADirector4,100$56.7KMar 12, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 14, 2026Cadian Capital Management, LPSC 13G3,347,5747.5%Jun 30, 2026SEC filing
Jul 30, 2026BlackRock, Inc.SC 13G/A3,558,7358.0%Jun 30, 2026SEC filing
May 7, 2026First Light Asset Management, LLCSC 13G/A7,971,48618.0%Apr 30, 2026SEC filing
Apr 24, 2026BlackRock, Inc.SC 13G/A3,057,0396.9%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 17, 2026OrbiMed Capital LLCSC 13G/A00.0%Dec 31, 2025SEC filing
Feb 13, 2026BROWN ADVISORY INCSC 13G/A2,513,2685.8%Dec 31, 2025SEC filing
Feb 13, 2026American Century Mutual Funds, Inc.SC 13G/A1,779,5754.1%Dec 31, 2025SEC filing
Feb 12, 2026Champlain Investment Partners, LLCSC 13G2,108,9444.9%Sep 30, 2025SEC filing
Dec 5, 2025First Light Asset Management, LLCSC 13G5,046,06811.6%Nov 30, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Surgical & Medical Instruments & Apparatus (SIC 3841). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 15 Lobbying Disclosure Act filings named this company as client, 2017–2025; most common issues: Health Issues (14), Medical/Disease Research/Clinical Labs (10), Taxation/Internal Revenue Code (5).

Federal contracts: $383.0K in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$69.6K
FY2022$91.7K
FY2023$67.2K
FY2024$91.3K
FY2025$63.1K
FY2026$0

Largest awards collected

Award IDAgencyAmountStart
36C25225P0293Department of Veterans Affairs$23.1KFeb 5, 2025
36C25224P0505Department of Veterans Affairs$23.1KMar 21, 2024
36C25223P0636Department of Veterans Affairs$23.1KApr 20, 2023
36C26121P1213Department of Veterans Affairs$22.9KJun 29, 2021
36C24625P0674Department of Veterans Affairs$15.4KFeb 11, 2025

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Growth — Revenue up every year for 5 straight years

· Gross Profitability (Novy-Marx) — High gross profit relative to total assets

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Key figures

· Growth — Latest revenue: $200.9M · 5-yr revenue CAGR: 22.3% · Straight growth years: 6

· Gross Profitability (Novy-Marx) — Gross profit / assets: 67.0% · Gross margin: 79.6%

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold SIBN — ranked by lift, the co-holding pattern described in Methodology: BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) · Medline Inc. (MDLN) · 3M CO (MMM) · WEST PHARMACEUTICAL SERVICES INC (WST).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 2, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Sep 11, 20261.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing
Aug 3, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

BECTON DICKINSON & CO (BDX) · Track Record: how the signals scored · Practice timing on SIBN

One email a week: the week’s new filings and research. Subscribe free

← SHW  ·  SIMO →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.